Laurion Capital Management LP Merus N.V. Transaction History

Laurion Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 08, 2019	SELL	$11.09 - $15.83 $185,114 - $264,234	-16,692 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$11.46 - $20.81 $1.03 Million - $1.87 Million	-89,904 Reduced 84.34%	16,692 $234,000
Q3 2018 Nov 13, 2018	BUY	$18.47 - $26.39 $1.97 Million - $2.81 Million	106,596 New	106,596 $2.1 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.94B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.